CD4+ cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy

Mona R. Loutfy; Sharon L. Walmsley; Christopher M. Mullin; George Perez; James D. Neaton

doi:10.1086/466537

CD4⁺ cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy

Mona R. Loutfy
, Sharon L. Walmsley
, Christopher M. Mullin
, George Perez
, James D. Neaton

Biostatistics

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

The relationship between 12-month CD4⁺ cell count response and clinical outcome (AIDS-defining event or death) in a subset of 228 patients with a human immunodeficiency virus load >400 copies/mL despite receiving combination antiretroviral therapy as part of a larger randomized trial was defined by use of Cox models. The 12-month CD4⁺ cell count responses were divided into 5 categories, ranging from decrease or no change (29% of patients) to a ≥100-cell/mm³ increase (27% of patients). There was a lower risk of clinical progression for each incremental increase in CD4 ⁺ cell count response. A 25-cell/mm³ increase in CD4 ⁺ cell count was associated with a 21% reduction in the risk of an AIDS-defining event or death (P<.0001).

Original language	English (US)
Pages (from-to)	1407-1411
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	192
Issue number	8
DOIs	https://doi.org/10.1086/466537
State	Published - Oct 15 2005

Bibliographical note

Funding Information:
Received 24 March 2005; accepted 24 May 2005; electronically published 9 September 2005. Presented in part: 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, 15 July 2003 (oral abstract 144). Potential conflicts of interest: none reported. Financial support: US National Institutes of Health; Canadian HIV Trials Network; Agouron Canada; Canadian Institutes of Health Research (salary support to M.R.L.); Ontario HIV Treatment Network (salary support to S.L.W.). a Present affiliation: Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Reprints or correspondence: Dr. James Neaton, University of Minnesota, 2221 University Ave. SE, Room 200, Minneapolis, MN 55414 ([email protected]).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1086/466537

Find It

Find It at U of M Libraries

Cite this

CD4⁺ cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. / Loutfy, Mona R.; Walmsley, Sharon L.; Mullin, Christopher M. et al.
In: Journal of Infectious Diseases, Vol. 192, No. 8, 15.10.2005, p. 1407-1411.

Research output: Contribution to journal › Article › peer-review

@article{38deebe62a1442e19b3935b6d4eeb105,

title = "CD4+ cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy",

abstract = "The relationship between 12-month CD4+ cell count response and clinical outcome (AIDS-defining event or death) in a subset of 228 patients with a human immunodeficiency virus load >400 copies/mL despite receiving combination antiretroviral therapy as part of a larger randomized trial was defined by use of Cox models. The 12-month CD4+ cell count responses were divided into 5 categories, ranging from decrease or no change (29\% of patients) to a ≥100-cell/mm3 increase (27\% of patients). There was a lower risk of clinical progression for each incremental increase in CD4 + cell count response. A 25-cell/mm3 increase in CD4 + cell count was associated with a 21\% reduction in the risk of an AIDS-defining event or death (P<.0001).",

author = "Loutfy, \{Mona R.\} and Walmsley, \{Sharon L.\} and Mullin, \{Christopher M.\} and George Perez and Neaton, \{James D.\}",

note = "Funding Information: Received 24 March 2005; accepted 24 May 2005; electronically published 9 September 2005. Presented in part: 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, 15 July 2003 (oral abstract 144). Potential conflicts of interest: none reported. Financial support: US National Institutes of Health; Canadian HIV Trials Network; Agouron Canada; Canadian Institutes of Health Research (salary support to M.R.L.); Ontario HIV Treatment Network (salary support to S.L.W.). a Present affiliation: Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Reprints or correspondence: Dr. James Neaton, University of Minnesota, 2221 University Ave. SE, Room 200, Minneapolis, MN 55414 ([email protected]).",

year = "2005",

month = oct,

day = "15",

doi = "10.1086/466537",

language = "English (US)",

volume = "192",

pages = "1407--1411",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - CD4+ cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy

AU - Loutfy, Mona R.

AU - Walmsley, Sharon L.

AU - Mullin, Christopher M.

AU - Perez, George

AU - Neaton, James D.

N1 - Funding Information: Received 24 March 2005; accepted 24 May 2005; electronically published 9 September 2005. Presented in part: 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, 15 July 2003 (oral abstract 144). Potential conflicts of interest: none reported. Financial support: US National Institutes of Health; Canadian HIV Trials Network; Agouron Canada; Canadian Institutes of Health Research (salary support to M.R.L.); Ontario HIV Treatment Network (salary support to S.L.W.). a Present affiliation: Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Reprints or correspondence: Dr. James Neaton, University of Minnesota, 2221 University Ave. SE, Room 200, Minneapolis, MN 55414 ([email protected]).

PY - 2005/10/15

Y1 - 2005/10/15

N2 - The relationship between 12-month CD4+ cell count response and clinical outcome (AIDS-defining event or death) in a subset of 228 patients with a human immunodeficiency virus load >400 copies/mL despite receiving combination antiretroviral therapy as part of a larger randomized trial was defined by use of Cox models. The 12-month CD4+ cell count responses were divided into 5 categories, ranging from decrease or no change (29% of patients) to a ≥100-cell/mm3 increase (27% of patients). There was a lower risk of clinical progression for each incremental increase in CD4 + cell count response. A 25-cell/mm3 increase in CD4 + cell count was associated with a 21% reduction in the risk of an AIDS-defining event or death (P<.0001).

AB - The relationship between 12-month CD4+ cell count response and clinical outcome (AIDS-defining event or death) in a subset of 228 patients with a human immunodeficiency virus load >400 copies/mL despite receiving combination antiretroviral therapy as part of a larger randomized trial was defined by use of Cox models. The 12-month CD4+ cell count responses were divided into 5 categories, ranging from decrease or no change (29% of patients) to a ≥100-cell/mm3 increase (27% of patients). There was a lower risk of clinical progression for each incremental increase in CD4 + cell count response. A 25-cell/mm3 increase in CD4 + cell count was associated with a 21% reduction in the risk of an AIDS-defining event or death (P<.0001).

UR - https://www.scopus.com/pages/publications/25844495820

UR - https://www.scopus.com/pages/publications/25844495820#tab=citedBy

U2 - 10.1086/466537

DO - 10.1086/466537

M3 - Article

C2 - 16170758

AN - SCOPUS:25844495820

SN - 0022-1899

VL - 192

SP - 1407

EP - 1411

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 8

ER -